SMT202100720T1 - Derivato di pirazolo pirimidinico e loro usi - Google Patents
Derivato di pirazolo pirimidinico e loro usiInfo
- Publication number
- SMT202100720T1 SMT202100720T1 SM20210720T SMT202100720T SMT202100720T1 SM T202100720 T1 SMT202100720 T1 SM T202100720T1 SM 20210720 T SM20210720 T SM 20210720T SM T202100720 T SMT202100720 T SM T202100720T SM T202100720 T1 SMT202100720 T1 SM T202100720T1
- Authority
- SM
- San Marino
- Prior art keywords
- pyrimidine derivative
- pyrazole pyrimidine
- pyrazole
- derivative
- pyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| EP16753709.1A EP3331877B1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202100720T1 true SMT202100720T1 (it) | 2022-01-10 |
Family
ID=56738143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20210720T SMT202100720T1 (it) | 2015-08-04 | 2016-08-04 | Derivato di pirazolo pirimidinico e loro usi |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10376511B2 (enExample) |
| EP (1) | EP3331877B1 (enExample) |
| JP (1) | JP7083309B2 (enExample) |
| KR (1) | KR102698366B1 (enExample) |
| CN (1) | CN108137562B (enExample) |
| AU (2) | AU2016304464B2 (enExample) |
| CA (1) | CA2994644A1 (enExample) |
| CY (1) | CY1124898T1 (enExample) |
| DK (1) | DK3331877T3 (enExample) |
| ES (1) | ES2901349T3 (enExample) |
| HR (1) | HRP20211949T1 (enExample) |
| HU (1) | HUE057607T2 (enExample) |
| IL (1) | IL257282B (enExample) |
| LT (1) | LT3331877T (enExample) |
| MX (1) | MX384172B (enExample) |
| PL (1) | PL3331877T3 (enExample) |
| PT (1) | PT3331877T (enExample) |
| RS (1) | RS62728B1 (enExample) |
| RU (1) | RU2735522C2 (enExample) |
| SI (1) | SI3331877T1 (enExample) |
| SM (1) | SMT202100720T1 (enExample) |
| WO (1) | WO2017021969A1 (enExample) |
| ZA (1) | ZA201800671B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3331877T3 (da) * | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
| JP7142646B2 (ja) * | 2017-02-01 | 2022-09-27 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | がんを治療するためのｃｋ１及び／又はｉｒａｋ１インヒビターとしてのｎ１－（４－（５－（シクロプロピルメチル）－１－メチル－１ｈ－ピラゾール－４－イル）ピリジン－２－イル）シクロヘキサン－１，４－ジアミン誘導体及び関連化合物 |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| US20200383984A1 (en) * | 2018-02-08 | 2020-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| IL288547B2 (en) * | 2019-06-03 | 2025-10-01 | Biotheryx Inc | Non-hygroscopic crystalline pyrazole compound salts, pharmaceutical preparations thereof and use thereof |
| CN114127058B (zh) * | 2019-07-04 | 2024-06-25 | 深圳国顺康医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| MX2022004390A (es) | 2019-10-11 | 2022-08-08 | Incyte Corp | Aminas biciclicas como inhibidores de la cinasa dependiente de ciclina 2 (cdk2). |
| US20230047732A1 (en) * | 2020-01-13 | 2023-02-16 | Biotheryx, Inc. | Pyrazolylpyrimidines and use thereof |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| KR20220158060A (ko) * | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제로서의 아릴 피페리딘 |
| CA3212624A1 (en) * | 2021-03-24 | 2022-09-29 | Kyle W.H. Chan | Pyrazolylpyrimidines for treating malignant solid tumor |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) * | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US20230053307A1 (en) * | 2021-07-19 | 2023-02-16 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating skin disorders and conditions |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2025199440A1 (en) * | 2024-03-21 | 2025-09-25 | Edgewood Oncology | Methods of treating liposarcoma using a pyrazole compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020111353A1 (en) * | 2000-12-05 | 2002-08-15 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| AU2002308748A1 (en) * | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| CN101693695A (zh) | 2004-03-30 | 2010-04-14 | 大正制药株式会社 | 嘧啶衍生物以及与其应用有关的治疗方法 |
| JP2007145819A (ja) * | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| JP2009538352A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ アクチボラグ | 細胞増殖を阻害するための薬剤としての２−カルボシクロアミノ−４−イミダゾリルピリミジン類 |
| CA2707989A1 (en) * | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| RU2674017C2 (ru) | 2011-11-04 | 2018-12-04 | ДЖАСКО ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Аминопиримидиновые ингибиторы киназ |
| CN106232122A (zh) * | 2013-09-27 | 2016-12-14 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| EP3057956B1 (en) * | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| DK3331877T3 (da) * | 2015-08-04 | 2022-01-03 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Pyrazolpyrimidinderivat og anvendelser deraf |
| JP7142646B2 (ja) * | 2017-02-01 | 2022-09-27 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | がんを治療するためのｃｋ１及び／又はｉｒａｋ１インヒビターとしてのｎ１－（４－（５－（シクロプロピルメチル）－１－メチル－１ｈ－ピラゾール－４－イル）ピリジン－２－イル）シクロヘキサン－１，４－ジアミン誘導体及び関連化合物 |
| US20200383984A1 (en) | 2018-02-08 | 2020-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
-
2016
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 SM SM20210720T patent/SMT202100720T1/it unknown
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en not_active Ceased
- 2016-08-04 MX MX2018001395A patent/MX384172B/es unknown
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
- 2016-08-04 KR KR1020187006128A patent/KR102698366B1/ko active Active
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
-
2018
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
-
2024
- 2024-02-05 US US18/432,931 patent/US20250049793A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800671B (en) | Pyrazole pyrimidine derivative and uses thereof | |
| IL258180B (en) | Heterocyclic compounds and their uses | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| EP3099677A4 (en) | Diaminopyrimidine benzenesulfone derivatives and uses thereof | |
| EP3268362A4 (en) | Substituted pyridines and uses thereof | |
| EP3097078A4 (en) | Pyridines and pyrimidines and use thereof | |
| IL247426A0 (en) | Pyrazole amide derivatives, preparations containing them and their uses | |
| PT3357922T (pt) | Composto de pirimidina ou piridopiridona e sua aplicação | |
| SG11201706029VA (en) | Anti-senescence compounds and uses thereof | |
| IL246630B (en) | History of pyrimidine pyrazolyl and pharmaceutical preparations containing them | |
| IL297057B2 (en) | Conjunctions and their uses | |
| IL247148A0 (en) | Pyrazolone compounds and uses thereof | |
| ZA201705456B (en) | Benzoxaborole compounds and uses thereof | |
| GB201504763D0 (en) | Compounds and uses | |
| SG11201803357TA (en) | Pyrimidine derivative | |
| IL254241A0 (en) | Etv2 and its uses | |
| IL253459A0 (en) | Isoergoline compounds and their uses | |
| GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
| GB2543375B (en) | Compounds and their uses | |
| AU201610551S (en) | Wardrobe | |
| AU2016041V (en) | Primaris Diplotaxis tenuifolia | |
| GB201514761D0 (en) | Preparation and uses of pyrimidinone derivatives |